Castle Biosciences (CSTL) to Announce Earnings on Thursday

Castle Biosciences (NASDAQ:CSTL) is projected to release its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect the company to post earnings of ($0.44) per share and revenue of $86.2360 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings results on Wednesday, May 6th. The company reported ($0.49) earnings per share for the quarter, meeting the consensus estimate of ($0.49). Castle Biosciences had a negative return on equity of 2.77% and a negative net margin of 3.78%.The firm had revenue of $84.23 million for the quarter, compared to analysts’ expectations of $79.23 million. On average, analysts expect Castle Biosciences to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Castle Biosciences Price Performance

CSTL stock opened at $24.44 on Tuesday. The firm has a 50 day moving average of $22.30 and a 200-day moving average of $26.83. The firm has a market capitalization of $741.27 million, a P/E ratio of -55.55 and a beta of 1.00. Castle Biosciences has a 12 month low of $14.59 and a 12 month high of $44.28. The company has a current ratio of 6.75, a quick ratio of 6.53 and a debt-to-equity ratio of 0.02.

Analyst Upgrades and Downgrades

CSTL has been the subject of a number of recent analyst reports. Canaccord Genuity Group reduced their price target on shares of Castle Biosciences from $50.00 to $40.00 and set a “buy” rating for the company in a research report on Monday, April 20th. Roth Capital began coverage on Castle Biosciences in a research report on Wednesday, June 24th. They set a “buy” rating and a $40.00 target price for the company. KeyCorp set a $35.00 target price on Castle Biosciences in a research note on Friday, May 29th. Zacks Research cut Castle Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 26th. Finally, Weiss Ratings downgraded Castle Biosciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 1st. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $42.43.

Insiders Place Their Bets

In related news, COO Kristen M. Oelschlager sold 8,586 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $24.42, for a total value of $209,670.12. Following the completion of the transaction, the chief operating officer directly owned 21,874 shares in the company, valued at approximately $534,163.08. The trade was a 28.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Derek J. Maetzold sold 3,622 shares of the stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $24.29, for a total value of $87,978.38. Following the completion of the transaction, the insider directly owned 12,368 shares in the company, valued at approximately $300,418.72. This represents a 22.65% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 45,189 shares of company stock valued at $1,014,561 over the last ninety days. 6.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Castle Biosciences

Institutional investors have recently modified their holdings of the company. HRT Financial LP lifted its position in Castle Biosciences by 0.9% in the 4th quarter. HRT Financial LP now owns 47,654 shares of the company’s stock worth $1,853,000 after buying an additional 415 shares during the last quarter. Franklin Resources Inc. raised its stake in shares of Castle Biosciences by 0.5% during the third quarter. Franklin Resources Inc. now owns 99,787 shares of the company’s stock worth $2,272,000 after acquiring an additional 540 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Castle Biosciences by 4.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,441 shares of the company’s stock worth $309,000 after acquiring an additional 655 shares in the last quarter. Federated Hermes Inc. bought a new stake in shares of Castle Biosciences in the 4th quarter worth approximately $26,000. Finally, Kemnay Advisory Services Inc. purchased a new stake in shares of Castle Biosciences in the 4th quarter valued at $35,000. 92.60% of the stock is currently owned by institutional investors.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.